Hey, I don't know why more people aren't talking about this, so here I go doing my best to articulate how excited I am for this stock.
# What the hell is it?
Autolus Therapeutics is a biopharmaceutical company specializing in CAR-T cell therapies aimed at treating various cancers. Their flagship product, Aucatzyl (obecabtagene autoleucel), targets relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).
# Recent Developments
* **FDA Approval:** On November 8, 2024, the FDA approved Aucatzyl for adult patients with r/r B-ALL, marking a significant milestone for the company. ([Yahoo Finance](https://finance.yahoo.com/news/autolus-therapeutics-reports-third-quarter-120000687.html?utm_source=chatgpt.com))
* **Clinical Data Publication:** The New England Journal of Medicine published data from the pivotal Phase 1b/2 FELIX study of Aucatzyl, reporting a 76.6% overall response rate with a low incidence of severe immune-related toxicities. Needless to say, this is a huge deal.
# Financial Health
As of Q3 September 30, 2024, Autolus reported:
* **Cash and Cash Equivalents:** $657.1 million, up from $239.6 million as of December 31, 2023. ([Yahoo Finance](https://finance.yahoo.com/news/autolus-therapeutics-reports-third-quarter-120000687.html?utm_source=chatgpt.com))
* **Total Operating Expenses:** $67.9 million for Q3 2024, compared to $42.9 million for the same period in 2023.
* **Net Loss:** $82.1 million for Q3 2024, up from $45.8 million in Q3 2023.
The company estimates that its current cash reserves are sufficient to support the full launch and commercialization of Aucatzyl in r/r adult B-ALL, as well as advance its pipeline development plans.
# Technical Analysis
(Take this part with a grain of salt, because I'm 100% regurgitating the information I found.) The stock is trading above its short-term and long-term moving averages, indicating a potential bullish trend.
* **Relative Strength Index (RSI):** 14-day RSI is at 37.34%, suggesting the stock is approaching oversold territory.
* **Stochastic Oscillator:** 14-day value at 31.91%, also indicating potential oversold conditions.
* **MACD:** The MACD line is below the signal line, a bearish indicator suggesting downward momentum.
* **Support and Resistance Levels:**
* **Support:** $2.80
* **Resistance:** $3.50
Breaking above the $3.50 resistance could signal a bullish reversal, while dropping below the $2.80 support may lead to further declines.
# Bull Case
* **Regulatory Milestone:** FDA approval of Aucatzyl positions Autolus as a key player in the CAR-T therapy market.
* **Strong Clinical Data:** High response rates with low toxicity enhance the therapy's market potential.
* **Solid Cash Position:** With over $657 million in cash, the company is well-funded for commercialization and pipeline development.
* **Analyst Optimism:** Analysts have set **an average price target of $10.20**, suggesting significant upside potential. ([Stock Analysis](https://stockanalysis.com/stocks/autl/forecast/?utm_source=chatgpt.com))
# Bear Case
* **Market Competition:** The CAR-T therapy space is competitive, with established players like Novartis and Gilead.
* **Financial Losses:** Increasing net losses may raise concerns about long-term profitability.
* **Execution Risks:** Challenges in manufacturing, distribution, and market adoption could impact commercial success.
# Conclusion
Autolus Therapeutics has achieved significant milestones with the FDA approval of Aucatzyl and promising clinical data. While the stock has experienced recent volatility, sure, the long-term outlook appears positive, especially considering the potential market impact of their CAR-T therapies. Therefore, especially considering that analysts believe this is either a strong buy or simply undervalued, this is a great play for the next 12 months. That being said, you do you, and manage your own risks. **Biotech is notoriously high risk, high reward, so keep that in mind.**
My position is 3,770 shares.
Edit: Now at 3,850 shares @$3.17.
Update 1/2/25: Averaged down to $2.70, 7000 shares. Yahoo finance has since wrote two articles so far about $AUTL, with one referencing this post.
https://finance.yahoo.com/news/why-autolus-therapeutics-autl-one-194339073.html
https://finance.yahoo.com/news/autolus-therapeutics-plc-autl-bull-001226399.html
This is for amusement purposes and should not be considered as financial advice.